US9447143B2ExpiredUtilityA1
Peptide fragments for inducing synthesis of extracellular matrix proteins
Est. expiryJun 13, 2026(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/12A61P 17/16A61P 17/02A61P 17/00A61K 38/07A61K 9/0014C07K 5/1024A61Q 19/00A61K 2300/00A61K 8/65A61K 38/00C07K 5/1008C07K 14/78A61K 9/06A61Q 19/08A61K 8/64C07K 5/1002A61K 2121/00
67
PatentIndex Score
0
Cited by
19
References
9
Claims
Abstract
Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A tetrapeptide capable of inducing production of extracellular matrix proteins, wherein the amino acid sequence of the tetrapeptide consists of SEQ ID NO: 1 having an acid or amidated carboxy-terminus.
2. A tetrapeptide capable of inducing production of extracellular matrix proteins, wherein the amino acid sequence of the tetrapeptide consists of SEQ ID NO:14 having an amidated carboxy-terminus.
3. A composition comprising a tetrapeptide of claim 1 and a pharmaceutically acceptable carrier.
4. A skincare composition comprising an emulsion of a tetrapeptide consisting of SEQ ID NO:1 or SEQ ID NO:14, and a dermatologically acceptable carrier.
5. The skincare composition of claim 4 , wherein the dermatologically acceptable carrier is a lotion, cream, paste, or ointment.
6. The composition of claim 4 , wherein the tetrapeptide is SEQ ID NO:1.
7. The composition of claim 4 , wherein the tetrapeptide is SEQ ID NO:14.
8. The composition of claim 4 , wherein the tetrapeptide is present in an effective concentration ranging from about 0.1 μg/ml to about 50 μg/mL.
9. The composition of claim 4 which further comprises a retinoid.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.